Gilead PD-1/PD-L1 inhibitors, cancer treatment compounds

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted Gilead Sciences, Inc. Patent US12590062B2 for PD-1/PD-L1 inhibitor compounds for cancer treatment. The patent covers compounds according to formula (I), methods of using said compounds singly or in combination with additional agents, and compositions for treating cancer. Application No. 17098171 was filed November 13, 2020, and the patent contains 18 claims.

View original document View source feed page

What changed

USPTO issued Patent US12590062B2 to Gilead Sciences, Inc. on March 31, 2026, covering PD-1/PD-L1 inhibitor compounds and their use in cancer treatment. The patent includes 18 claims and lists 30 named inventors across various chemical compound formulas. CPC classifications span multiple therapeutic and chemical categories including A61P 35/00 (anti-neoplastic) and various C07D heterocyclic compound classifications.

This is a routine patent grant notification with no compliance obligations. Pharmaceutical companies developing or commercializing PD-1/PD-L1 inhibitor therapies should review the patent claims to assess potential licensing needs or freedom-to-operate concerns. Third parties should conduct due diligence to determine whether their activities fall within the scope of the granted claims.

Source document (simplified)

← USPTO Patent Grants

PD-1/PD-L1 inhibitors

Grant US12590062B2 Kind: B2 Mar 31, 2026

Assignee

Gilead Sciences, Inc.

Inventors

Evangelos Aktoudianakis, Todd Appleby, Aesop Cho, Zhimin Du, Michael Graupe, Juan A. Guerrero, Salman Y. Jabri, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Gregory Notte, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus

Abstract

Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.

CPC Classifications

A61K 31/5377 A61K 31/44 A61K 31/444 A61K 31/4545 A61K 31/497 A61K 45/06 C07D 213/85 C07D 295/088 C07D 491/107 C07D 401/12 C07D 405/12 C07D 413/12 C07D 213/69 C07D 213/30 C07D 213/61 C07D 213/64 C07D 401/04 C07D 401/14 C07D 405/14 C07D 487/08 C07D 487/10 C07D 498/04 C07D 519/00 C07D 417/14 C07D 487/04 C07D 471/04 A61P 35/02 A61P 35/00